Bicara Therapeutics Inc. $BCAX Stock Holdings Lessened by Algert Global LLC

Key Points

• Algert Global reduced its Bicara Therapeutics stake by 29.5% in the second quarter, selling 97,601 shares and retaining 233,232 shares valued at approximately $6.9 million.
• Bicara insiders have also been selling: the COO and CFO sold shares under pre-arranged Rule 10b5-1 plans, contributing to 108,000 insider shares sold worth about $3.1 million over the past three months.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $32.64 price target versus the stock’s reported opening price of $24.73; the company reported quarterly EPS of -$0.82, in line with estimates.

Algert Global LLC cut its holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 29.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 233,232 shares of the company's stock after selling 97,601 shares during the period. Algert Global LLC owned about 0.35% of Bicara Therapeutics worth $6,925,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of BCAX. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Bicara Therapeutics during the fourth quarter valued at approximately $45,000. Legal & General Group Plc raised its position in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after purchasing an additional 1,233 shares during the period. Larson Financial Group LLC raised its position in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after purchasing an additional 3,595 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after purchasing an additional 3,866 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock worth $97,000 after purchasing an additional 4,585 shares during the last quarter.

Insiders Place Their Bets

In other news, COO Ryan Cohlhepp sold 18,750 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $524,625.00. Following the completion of the sale, the chief operating officer directly owned 181,641 shares of the company's stock, valued at approximately $5,082,315.18. This represents a 9.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 12,500 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.97, for a total transaction of $349,625.00. Following the completion of the transaction, the chief financial officer owned 129,855 shares of the company's stock, valued at $3,632,044.35. This trade represents a 8.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 108,000 shares of company stock worth $3,079,236. 13.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on BCAX shares. Citigroup reaffirmed a "market outperform" rating on shares of Bicara Therapeutics in a research report on Friday, August 21st. Morgan Stanley boosted their price target on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the company an "overweight" rating in a report on Tuesday, August 11th. Wells Fargo & Company upped their price target on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Finally, The Goldman Sachs Group increased their price objective on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bicara Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $32.64.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $24.73 on Thursday. Bicara Therapeutics Inc. has a one year low of $10.30 and a one year high of $30.99. The stock's fifty day moving average is $26.68 and its 200-day moving average is $22.30. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -7.98 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting the consensus estimate of ($0.82). Analysts forecast that Bicara Therapeutics Inc. will post -3.45 EPS for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source